Amneal Pharmaceuticals, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Amneal executed Amendment No. 3 on August 3, 2026, refinancing $2,084,263,125 of Amendment No. 2 Term Loans. Existing lenders converted their loans via cashless exchange ($2,039,082,634.93); JPMorgan provided additional $45.2M to pay out non-converting lenders. New pricing: ABR margin 1.50% (down from 2.00%), Term Benchmark margin 2.50% (down from 3.00%). Maturity remains August 1, 2032. No change to principal amount or material covenants.
Why this rating
Refinancing reduces borrowing costs modestly; modest rate reduction relative to $2.1B facility size. Routine capital structure management for $1.7B company. No business risk or opportunity change.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.